RayKnowChina Research Map
Shortlist0

RecruitingPrimary sclerosing cholangitisPhase 3

Registered title, quoted from ClinicalTrials.gov

A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing Cholangitis

An open trial on primary sclerosing cholangitis, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 11 hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 13 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 11

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Study siteBeijing Ditan Hospital, Capital Medical University首都医科大学附属北京地坛医院BeijingHospital page
  2. Study siteBeijing Friendship Hospital首都医科大学附属北京友谊医院BeijingHospital page
  3. Study siteFirst Hospital of Jilin University吉林大学第一医院ChangchunHospital page
  4. Study siteGuangzhou Eighth People's Hospital广州市第八人民医院(嘉禾院区)GuangzhouHospital page
  5. Study siteHenan Provincial People's Hospital河南省人民医院ZhengzhouHospital page
  6. Study sitePeking Union Medical College Hospital北京协和医院BeijingHospital page
  7. Study sitePeking University People's Hospital北京大学人民医院BeijingHospital page
  8. Study siteQilu Hospital of Shandong University山东大学齐鲁医院JinanHospital page
  9. Study siteRenji Hospital上海交通大学医学院附属仁济医院ShanghaiHospital page
  10. Study siteSecond Affiliated Hospital of Nanchang University南昌大学第二附属医院NanchangHospital page
  11. Study siteTianjin Medical University General Hospital天津医科大学总医院TianjinHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07387549, read on 13 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 3

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (3 points)Hide the checklist
  1. 18 years to 75 years; sex: all

    Registered eligibility fields

  2. Known malignancy or history of malignancy within the last 5 years, with the exception of local, successfully treated basal cell carcinoma or in-situ carcinoma of the uterine cervix.

    Exclusion criterion 7

    Participant has or is known to have tested positive for human immunodeficiency virus (HIV) type 1 or 2 at SV.

    Exclusion criterion 18

  3. For female participants: known pregnancy, or has a positive serum pregnancy test, or lactating.

    Exclusion criterion 13

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; earlier treatment; day-to-day activity level; blood tests: counts, liver and kidney function; scans and measurable lesions.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07387549, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Adults participants aged 18 years or older
  • Confirmed diagnosis of primary sclerosing cholangitis based on standard clinical, biochemical, and imaging criteria
  • Compensated liver disease at screening
  • Stable background therapy, where applicable prior to study entry
  • Women of childbearing potential have to apply during the entire duration of the study a highly effective method of birth control
  • Ability to provide written informed consent and comply with study procedures.

Exclusion Criteria:

  • History or presence of other concomitant chronic liver disease
  • History of hepatic decompensation, including: i) History of liver transplantation, current MELD 3.0 score ≥12 due to hepatic impairment.

ii) Evidence of complications of cirrhosis

  • Participants with cirrhosis who are also classified as Child-Pugh B or C based on the Child Pugh score.
  • History of biliary intervention within 60 days prior to the screening period, and/or presence of percutaneous drain or bile duct stent at SV.
  • History of bacterial cholangitis, and/or participant on antibiotics for prophylaxis of recurrent cholangitis within 60 days prior to the SV.
  • History or any current suspicion of cholangiocarcinoma or hepatocellular carcinoma
  • Known malignancy or history of malignancy within the last 5 years, with the exception of local, successfully treated basal cell carcinoma or in-situ carcinoma of the uterine cervix.
  • Medical conditions that may cause non-hepatic increases in ALP (e.g. Paget's disease).
  • Administration of the following medications are prohibited as specified below:

i) 3 months prior to baseline: norucholic acid, fibrates, seladelpar and glitazones.

ii) 3 months prior to baseline: cyclosporine, mycophenolate, pentoxifylline, and chronic systemic corticosteroids (except as part of management of IBD at an ongoing stable dose); potentially hepatotoxic drugs (including α-methyl-dopa, sodium valproic acid, isoniazid, or nitrofurantoin).

  • Participants who are currently participating in, plan to participate in, or have participated in an investigational drug or medical device study containing active substance within 30 days or five half-lives, whichever is longer, prior to the SV. - Participants with previous exposure to elafibranor.
  • Electrocardiogram (ECG) with QT interval corrected by Fridericia's formula (QTcF) >450 msec in males or QTcF >470 msec in females for participants without bundle branch block.
  • Significant renal disease,
  • For female participants: known pregnancy, or has a positive serum pregnancy test, or lactating.
  • Regular alcohol intake in excess of the recommended limit of 2 standard drinks per day for men or 1 standard drink per day for women
  • History of alcohol abuse, or other substance abuse within 1 year prior to SV.
  • Sensitivity to any of the study interventions, or components thereof, or drug or other allergy that contraindicates participation in the study.
  • Mental instability or incompetence
  • Participant has or is known to have tested positive for human immunodeficiency virus (HIV) type 1 or 2 at SV.
  • Medical conditions that may diminish life expectancy to <2 years.

Quoted from ClinicalTrials.gov, NCT07387549, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07387549, read on 13 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07387549